i honestly think people will be pleasantly surprised. orbimed could have called in their money and auctioned off the business. amgen could have played harder ball but instead they committed a lot of money and time. management have stated no customers lost - yes timeframes have probably slipped but one single contract justifies current market cap. so if they can clear the decks, f* of any halfwits who are not contributing to the business and paint an outlook that shows revenues increasing over the coming years (next 2) then its onwards and upwards and people will look at these prices as silly. not sure much downside from these prices. unless ramin was a complete bellend and designed products for the fun of it, then we have a suite of leading products that customers want. if all we ever had were sanofi, hike, medimmune, amgen and abbvie - compelling investment case. but we do need to do something with the eye devices plus diabetes offering.
lord knows but all i know is we shall know one way or another soon!
UNS Price at posting:
8.8¢ Sentiment: Buy Disclosure: Held
